Compare TOUR & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TOUR | ACET |
|---|---|---|
| Founded | 2006 | 1947 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.0M | 71.3M |
| IPO Year | 2014 | N/A |
| Metric | TOUR | ACET |
|---|---|---|
| Price | $0.67 | $8.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $65.33 |
| AVG Volume (30 Days) | 131.9K | ★ 208.6K |
| Earning Date | 03-13-2026 | 03-05-2026 |
| Dividend Yield | ★ 5.45% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $78,261,883.00 | N/A |
| Revenue This Year | $12.27 | N/A |
| Revenue Next Year | $10.18 | N/A |
| P/E Ratio | $101.02 | ★ N/A |
| Revenue Growth | ★ 9.07 | N/A |
| 52 Week Low | $0.62 | $7.15 |
| 52 Week High | $1.17 | $17.44 |
| Indicator | TOUR | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 40.73 | 78.42 |
| Support Level | $0.62 | $7.76 |
| Resistance Level | $0.70 | $8.55 |
| Average True Range (ATR) | 0.03 | 0.45 |
| MACD | -0.00 | -0.14 |
| Stochastic Oscillator | 1.78 | 73.85 |
Tuniu Corp is an online leisure travel company. The company is engaged in the provision of travel-related services in the People's Republic of China. It offers a large selection of packaged tours, including organized tours and self-guided tours, as well as travel-related services for leisure travelers. The company's organized tours provide pre-arranged itineraries, transportation, accommodations, entertainment, meals, and tour guide services. Its self-guided tours consist of combinations of flights and hotel bookings and other optional add-ons. The company derives almost all of its revenue from PRC.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.